CD79A and infection: Follow-on studies will also be needed to explore whether an anti-S IgA response is detectable at the site of disease, i.e., the lungs, following natural infection, as well as whether absence of an anti-S IgA response in blood or mucosal samples correlates with increased susceptibility to SARS-CoV-2 infection in PLWH.